Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors

MrDecoder · 2026-03-06T09:07:03+00:00

A recent obesity trial result has raised concerns for Novo Nordisk while benefiting Eli Lilly in the competitive GLP-1 market, impacting investor confidence.

MrDecoder

2026-03-06 09:07:03

Abstract generation in progress

A surprising obesity trial result has shaken confidence in Novo Nordisk (NVO +1.38%) and sharpened the spotlight on Eli Lilly (LLY 2.03%) in this fiercely competitive GLP‑1 race. Watch the video below to see what it could mean for investors.

*This video was published on Feb.24, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.